Stock Events

Stock Events

Chemomab Therapeutics 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-7.9MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2QV0.MU. It's not an investment recommendation.
Alibaba Group
4
BABA
VICI Properties
3
VICI
Vale.
3
VALE
Quantum Computing
3
QUBT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Lakefront Biotherapeutics NV
GLPG
Mkt Cap1.86B
Galapagos NV specializes in drug discovery for fibrosis and inflammatory diseases, overlapping with Chemomab's research areas.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.18B
Madrigal Pharmaceuticals is involved in developing therapies for fibrosis and NASH, similar to Chemomab's focus areas.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences has a strong portfolio in liver diseases, including fibrosis and NASH, competing with Chemomab's pipeline.
Viking Therapeutics
VKTX
Mkt Cap4.35B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, directly competing with Chemomab.
Agenus
AGEN
Mkt Cap126.18M
Agenus Inc. is involved in immuno-oncology but also explores inflammatory diseases, potentially overlapping with Chemomab's therapeutic areas.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie has a broad portfolio that includes treatments for inflammatory diseases, indirectly competing with Chemomab in the broader market for anti-inflammatory treatments.

About

Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
Show more...
CEO
Dr. Adi Mor George Ph.D.
Employees
20
Country
Israel
ISIN
US16385C1045

Listings

MU
DE
2QV0.MU
STU
DE
2QV.STU
STU
DE
2QV0.STU
MU
DE
2QV.MU

0 Comments

Share your thoughts

FAQ

What is Chemomab Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Chemomab Therapeutics stocks are traded under the ticker 2QV0.MU.
What is Chemomab Therapeutics revenue for the last year?▼
Chemomab Therapeutics revenue for the last year amounts to 0 EUR.
What is Chemomab Therapeutics net income for the last year?▼
2QV0.MU net income for the last year is -7.9M EUR.
How many employees does Chemomab Therapeutics have?▼
As of July 11, 2026, the company has 20 employees.
In which sector is Chemomab Therapeutics located?▼
Chemomab Therapeutics operates in the Health & Wellness sector.
When did Chemomab Therapeutics complete a stock split?▼
Chemomab Therapeutics has not had any recent stock splits.
Where is Chemomab Therapeutics headquartered?▼
Chemomab Therapeutics is headquartered in Tel Aviv-Yafo, Israel.